Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia

Calcium-based and non-calcium-based phosphate binders have similar efficacy in the treatment of hyperphosphatemia; however, calcium-based binders may be associated with hypercalcemia, vascular calcification, and adynamic bone disease. A analysis was carried out of data from a 16-week, Phase IV study...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drugs in Context 2017, Vol.6, p.212302-12
Hauptverfasser: Wilson, Rosamund J, Copley, J Brian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 12
container_issue
container_start_page 212302
container_title Drugs in Context
container_volume 6
creator Wilson, Rosamund J
Copley, J Brian
description Calcium-based and non-calcium-based phosphate binders have similar efficacy in the treatment of hyperphosphatemia; however, calcium-based binders may be associated with hypercalcemia, vascular calcification, and adynamic bone disease. A analysis was carried out of data from a 16-week, Phase IV study of patients with end-stage renal disease (ESRD) who switched to lanthanum carbonate monotherapy from baseline calcium acetate/calcium carbonate monotherapy. Of the intent-to-treat population (N=2520), 752 patients with recorded dose data for calcium acetate (n=551)/calcium carbonate (n=201) at baseline and lanthanum carbonate at week 16 were studied. Elemental calcium intake, serum phosphate, corrected serum calcium, and serum intact parathyroid hormone levels were analyzed. Of the 551 patients with calcium acetate dose data, 271 (49.2%) had an elemental calcium intake of at least 1.5 g/day at baseline, and 142 (25.8%) had an intake of at least 2.0 g/day. Mean (95% confidence interval [CI]) serum phosphate levels were 6.1 (5.89, 6.21) mg/dL at baseline and 6.2 (6.04, 6.38) mg/dL at 16 weeks; mean (95% CI) corrected serum calcium levels were 9.3 (9.16, 9.44) mg/dL and 9.2 (9.06, 9.34) mg/dL, respectively. Of the 201 patients with calcium carbonate dose data, 117 (58.2%) had an elemental calcium intake of at least 1.5 g/day, and 76 (37.8%) had an intake of at least 2.0 g/day. Mean (95% CI) serum phosphate levels were 5.8 (5.52, 6.06) mg/dL at baseline and 5.8 (5.53, 6.05) mg/dL at week 16; mean (95% CI) corrected serum calcium levels were 9.7 (9.15, 10.25) mg/dL and 9.2 (9.06, 9.34) mg/dL, respectively. Calcium acetate/calcium carbonate phosphate binders, taken to control serum phosphate levels, may result in high levels of elemental calcium intake. This may lead to complications related to calcium balance.
doi_str_mv 10.7573/dic.212302
format Article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5279921</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_4ef86092d37842128474144b14d79775</doaj_id><sourcerecordid>1866696230</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3592-7419cd8458690c420a50ab18ca284cfddc1a88bb9518001c11ed96db67ee96f83</originalsourceid><addsrcrecordid>eNpVkU9PFTEUxRuiAQQ2fgAzS2My0Hb6d2NiCCoJiRtdN3faO0xx5nVs52H49hYevMiqveee_m7bQ8h7Rs-11N1FiP6cM95RfkCOmRa0FZ01b572smXWsCPyrpQ7SoWkSh2SI26Y4UzwY7JcTTjjZoWp8TD5uJ2bWKvf2EApyUdYMTR_4zru2-BxrerFS-0h92lTlXqwWUds1oywPjKbNDTjw4J5GVNZxmqZI5yStwNMBc-e1xPy6-vVz8vv7c2Pb9eXX25a30nLWy2Y9cEIaZSlXnAKkkLPjAduhB9C8AyM6XsrmaGUecYwWBV6pRGtGkx3Qq533JDgzi05zpAfXILonoSUbx3kNfoJncDBKGp56LQR9SONqNOF6JkI2motK-vzjrVs-xmDr2_LML2Cvu5s4uhu072TXFvLWQV8fAbk9GeLZXVzLB6nCTaYtsUxo5SyqkZYrZ92Vp9TKRmH_RhG3WPcrsbtdnFX84f_L7a3vuTb_QOu0qcx</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1866696230</pqid></control><display><type>article</type><title>Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Wilson, Rosamund J ; Copley, J Brian</creator><creatorcontrib>Wilson, Rosamund J ; Copley, J Brian</creatorcontrib><description>Calcium-based and non-calcium-based phosphate binders have similar efficacy in the treatment of hyperphosphatemia; however, calcium-based binders may be associated with hypercalcemia, vascular calcification, and adynamic bone disease. A analysis was carried out of data from a 16-week, Phase IV study of patients with end-stage renal disease (ESRD) who switched to lanthanum carbonate monotherapy from baseline calcium acetate/calcium carbonate monotherapy. Of the intent-to-treat population (N=2520), 752 patients with recorded dose data for calcium acetate (n=551)/calcium carbonate (n=201) at baseline and lanthanum carbonate at week 16 were studied. Elemental calcium intake, serum phosphate, corrected serum calcium, and serum intact parathyroid hormone levels were analyzed. Of the 551 patients with calcium acetate dose data, 271 (49.2%) had an elemental calcium intake of at least 1.5 g/day at baseline, and 142 (25.8%) had an intake of at least 2.0 g/day. Mean (95% confidence interval [CI]) serum phosphate levels were 6.1 (5.89, 6.21) mg/dL at baseline and 6.2 (6.04, 6.38) mg/dL at 16 weeks; mean (95% CI) corrected serum calcium levels were 9.3 (9.16, 9.44) mg/dL and 9.2 (9.06, 9.34) mg/dL, respectively. Of the 201 patients with calcium carbonate dose data, 117 (58.2%) had an elemental calcium intake of at least 1.5 g/day, and 76 (37.8%) had an intake of at least 2.0 g/day. Mean (95% CI) serum phosphate levels were 5.8 (5.52, 6.06) mg/dL at baseline and 5.8 (5.53, 6.05) mg/dL at week 16; mean (95% CI) corrected serum calcium levels were 9.7 (9.15, 10.25) mg/dL and 9.2 (9.06, 9.34) mg/dL, respectively. Calcium acetate/calcium carbonate phosphate binders, taken to control serum phosphate levels, may result in high levels of elemental calcium intake. This may lead to complications related to calcium balance.</description><identifier>ISSN: 1745-1981</identifier><identifier>ISSN: 1740-4398</identifier><identifier>EISSN: 1740-4398</identifier><identifier>DOI: 10.7573/dic.212302</identifier><identifier>PMID: 28182142</identifier><language>eng</language><publisher>England: Just Medical Media Limited</publisher><subject>calcium acetate ; calcium carbonate ; calcium phosphates ; chronic kidney failure ; elemental calcium intake ; hyperphosphatemia ; lanthanum carbonate ; Original Research</subject><ispartof>Drugs in Context, 2017, Vol.6, p.212302-12</ispartof><rights>Copyright © 2017 Wilson RJ, Copley JB 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3592-7419cd8458690c420a50ab18ca284cfddc1a88bb9518001c11ed96db67ee96f83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279921/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279921/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28182142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wilson, Rosamund J</creatorcontrib><creatorcontrib>Copley, J Brian</creatorcontrib><title>Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia</title><title>Drugs in Context</title><addtitle>Drugs Context</addtitle><description>Calcium-based and non-calcium-based phosphate binders have similar efficacy in the treatment of hyperphosphatemia; however, calcium-based binders may be associated with hypercalcemia, vascular calcification, and adynamic bone disease. A analysis was carried out of data from a 16-week, Phase IV study of patients with end-stage renal disease (ESRD) who switched to lanthanum carbonate monotherapy from baseline calcium acetate/calcium carbonate monotherapy. Of the intent-to-treat population (N=2520), 752 patients with recorded dose data for calcium acetate (n=551)/calcium carbonate (n=201) at baseline and lanthanum carbonate at week 16 were studied. Elemental calcium intake, serum phosphate, corrected serum calcium, and serum intact parathyroid hormone levels were analyzed. Of the 551 patients with calcium acetate dose data, 271 (49.2%) had an elemental calcium intake of at least 1.5 g/day at baseline, and 142 (25.8%) had an intake of at least 2.0 g/day. Mean (95% confidence interval [CI]) serum phosphate levels were 6.1 (5.89, 6.21) mg/dL at baseline and 6.2 (6.04, 6.38) mg/dL at 16 weeks; mean (95% CI) corrected serum calcium levels were 9.3 (9.16, 9.44) mg/dL and 9.2 (9.06, 9.34) mg/dL, respectively. Of the 201 patients with calcium carbonate dose data, 117 (58.2%) had an elemental calcium intake of at least 1.5 g/day, and 76 (37.8%) had an intake of at least 2.0 g/day. Mean (95% CI) serum phosphate levels were 5.8 (5.52, 6.06) mg/dL at baseline and 5.8 (5.53, 6.05) mg/dL at week 16; mean (95% CI) corrected serum calcium levels were 9.7 (9.15, 10.25) mg/dL and 9.2 (9.06, 9.34) mg/dL, respectively. Calcium acetate/calcium carbonate phosphate binders, taken to control serum phosphate levels, may result in high levels of elemental calcium intake. This may lead to complications related to calcium balance.</description><subject>calcium acetate</subject><subject>calcium carbonate</subject><subject>calcium phosphates</subject><subject>chronic kidney failure</subject><subject>elemental calcium intake</subject><subject>hyperphosphatemia</subject><subject>lanthanum carbonate</subject><subject>Original Research</subject><issn>1745-1981</issn><issn>1740-4398</issn><issn>1740-4398</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU9PFTEUxRuiAQQ2fgAzS2My0Hb6d2NiCCoJiRtdN3faO0xx5nVs52H49hYevMiqveee_m7bQ8h7Rs-11N1FiP6cM95RfkCOmRa0FZ01b572smXWsCPyrpQ7SoWkSh2SI26Y4UzwY7JcTTjjZoWp8TD5uJ2bWKvf2EApyUdYMTR_4zru2-BxrerFS-0h92lTlXqwWUds1oywPjKbNDTjw4J5GVNZxmqZI5yStwNMBc-e1xPy6-vVz8vv7c2Pb9eXX25a30nLWy2Y9cEIaZSlXnAKkkLPjAduhB9C8AyM6XsrmaGUecYwWBV6pRGtGkx3Qq533JDgzi05zpAfXILonoSUbx3kNfoJncDBKGp56LQR9SONqNOF6JkI2motK-vzjrVs-xmDr2_LML2Cvu5s4uhu072TXFvLWQV8fAbk9GeLZXVzLB6nCTaYtsUxo5SyqkZYrZ92Vp9TKRmH_RhG3WPcrsbtdnFX84f_L7a3vuTb_QOu0qcx</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>Wilson, Rosamund J</creator><creator>Copley, J Brian</creator><general>Just Medical Media Limited</general><general>BioExcel Publishing Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>2017</creationdate><title>Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia</title><author>Wilson, Rosamund J ; Copley, J Brian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3592-7419cd8458690c420a50ab18ca284cfddc1a88bb9518001c11ed96db67ee96f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>calcium acetate</topic><topic>calcium carbonate</topic><topic>calcium phosphates</topic><topic>chronic kidney failure</topic><topic>elemental calcium intake</topic><topic>hyperphosphatemia</topic><topic>lanthanum carbonate</topic><topic>Original Research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wilson, Rosamund J</creatorcontrib><creatorcontrib>Copley, J Brian</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Drugs in Context</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wilson, Rosamund J</au><au>Copley, J Brian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia</atitle><jtitle>Drugs in Context</jtitle><addtitle>Drugs Context</addtitle><date>2017</date><risdate>2017</risdate><volume>6</volume><spage>212302</spage><epage>12</epage><pages>212302-12</pages><issn>1745-1981</issn><issn>1740-4398</issn><eissn>1740-4398</eissn><abstract>Calcium-based and non-calcium-based phosphate binders have similar efficacy in the treatment of hyperphosphatemia; however, calcium-based binders may be associated with hypercalcemia, vascular calcification, and adynamic bone disease. A analysis was carried out of data from a 16-week, Phase IV study of patients with end-stage renal disease (ESRD) who switched to lanthanum carbonate monotherapy from baseline calcium acetate/calcium carbonate monotherapy. Of the intent-to-treat population (N=2520), 752 patients with recorded dose data for calcium acetate (n=551)/calcium carbonate (n=201) at baseline and lanthanum carbonate at week 16 were studied. Elemental calcium intake, serum phosphate, corrected serum calcium, and serum intact parathyroid hormone levels were analyzed. Of the 551 patients with calcium acetate dose data, 271 (49.2%) had an elemental calcium intake of at least 1.5 g/day at baseline, and 142 (25.8%) had an intake of at least 2.0 g/day. Mean (95% confidence interval [CI]) serum phosphate levels were 6.1 (5.89, 6.21) mg/dL at baseline and 6.2 (6.04, 6.38) mg/dL at 16 weeks; mean (95% CI) corrected serum calcium levels were 9.3 (9.16, 9.44) mg/dL and 9.2 (9.06, 9.34) mg/dL, respectively. Of the 201 patients with calcium carbonate dose data, 117 (58.2%) had an elemental calcium intake of at least 1.5 g/day, and 76 (37.8%) had an intake of at least 2.0 g/day. Mean (95% CI) serum phosphate levels were 5.8 (5.52, 6.06) mg/dL at baseline and 5.8 (5.53, 6.05) mg/dL at week 16; mean (95% CI) corrected serum calcium levels were 9.7 (9.15, 10.25) mg/dL and 9.2 (9.06, 9.34) mg/dL, respectively. Calcium acetate/calcium carbonate phosphate binders, taken to control serum phosphate levels, may result in high levels of elemental calcium intake. This may lead to complications related to calcium balance.</abstract><cop>England</cop><pub>Just Medical Media Limited</pub><pmid>28182142</pmid><doi>10.7573/dic.212302</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1745-1981
ispartof Drugs in Context, 2017, Vol.6, p.212302-12
issn 1745-1981
1740-4398
1740-4398
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5279921
source DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects calcium acetate
calcium carbonate
calcium phosphates
chronic kidney failure
elemental calcium intake
hyperphosphatemia
lanthanum carbonate
Original Research
title Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T01%3A04%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elemental%20calcium%20intake%20associated%20with%20calcium%20acetate/calcium%20carbonate%20in%20the%20treatment%20of%20hyperphosphatemia&rft.jtitle=Drugs%20in%20Context&rft.au=Wilson,%20Rosamund%20J&rft.date=2017&rft.volume=6&rft.spage=212302&rft.epage=12&rft.pages=212302-12&rft.issn=1745-1981&rft.eissn=1740-4398&rft_id=info:doi/10.7573/dic.212302&rft_dat=%3Cproquest_doaj_%3E1866696230%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1866696230&rft_id=info:pmid/28182142&rft_doaj_id=oai_doaj_org_article_4ef86092d37842128474144b14d79775&rfr_iscdi=true